Publication at Faculty of Medicine in Pilsen |
2013
Abstract
In primarily unresectable liver metastases, neoadjuvant conversion systemic therapy with the use of modern chemotherapy regimens in combination with targeted biological therapy may allow for a radical surgical resection of metastatic foci in the liver. An optimal conversion regimen should be one with the least toxicity.
These criteria are met by the monoclonal antibody cetuximab. The present clinical case report demonstrates the use of cetuximab in conversion therapy for liver metastases that resulted in their radical resection.